Posted by Michael Wonder on 12 Aug 2023
Jacobio Pharma announces breakthrough therapy designation from China CDE for KRAS G12C inhibitor glecirasib for the treatment of pancreatic cancer
7 August 2023 - Jacobio Pharma today announced that Jacobio's in house KRAS G12C inhibitor glecirasib was granted breakthrough therapy designation by the Center for Drug Evaluation of the National Medical Products Administration for the pancreatic cancer patients with a KRAS G12C mutation who have progressed after frontline standard care treatment.
This breakthrough therapy designation was granted based on the clinical efficacy and safety data from ongoing gleciracib clinical trials.
